



Neurotech submits application for US FDA clearance of Mente Autism

KEY HIGHLIGHTS

Application for US FDA clearance submitted on schedule

Perth, Australia & Malta – 2 October 2018 – Neurotech International Limited (ASX: NTI) (“Neurotech” or “the Company”) is pleased to announce that it has reached another milestone following the submission of its Federal Drug Administration (FDA) clearance application for flagship product Mente Autism.

The Company is seeking clearance for Mente Autism using a de-novo application process and expects the approval process to take 9 – 12 months.

Wolfgang Storf, CEO of Neurotech, said: “This is another important milestone for the company. I am very proud of my team and for their outstanding efforts to prepare all the documentation and submit on schedule. Obtaining US FDA clearance would be a major achievement for Neurotech, allowing us to take the Mente Autism product into the largest market in the world. Ever since the publication of the clinical trial results we have seen a very encouraging surge in enquiries, and I am confident that with the device we are on the right track towards providing a proven therapy to children across the United States as well as other geographies.”

-ends-

About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech’s primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente Autism and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism.

Mente Autism is a clinical-quality EEG device that uses neurofeedback technology to help children with autism spectrum disorder. Designed for home use, it helps relax the minds of children on the spectrum which in turn helps them to focus better and engage positively with their environment.

Neurotech International Ltd

ABN 73 610 205 402

Level 14, 191 St Georges Terrace

Perth, Western Australia 6060

www.neurotechinternational.com

For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

Media enquiries

Matthew Wright

matt@nwrcommunications.com.au

Tel: +61 451 896 420